GLP-1 Agonists for Weight Loss: Low-Competition Class Query at 18.1K/mo

NovaPharmaNews Search Demand Index

Organic search volume (US). Snapshot 2026-06-17 from agent_keyword (DataForSEO sync).

Query	US monthly volume	Competition	Intent
glp-1 agonists for weight loss	18,100	0.01	informational
weight loss medications	165,000	1.00	informational

Read: The class query (18.1k/mo, competition 0.01) is far less contested than the head term (165k/mo, competition 1.00)—a deliberate SEO target for explanatory content on the GLP-1 agonist drug class.

Provenance: agent_keyword, region=us, retrieved 2026-06-18; cutoff 2026-06-17.

What are GLP-1 agonists for weight loss?

GLP-1 receptor agonists are incretin-mimetic drugs approved for chronic weight management in adults with obesity or overweight plus weight-related comorbidities. FDA Drugs@FDA lists NDA 215256 for semaglutide (Wegovy) as a GLP-1 agonist in this category, and FDA prescribing information describes the chronic weight-management indication. The EMA EPAR for Wegovy documents EU authorization for semaglutide weight management.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Pipeline and comparative trials

Sponsor	Asset	Mechanism	Registry
Novo Nordisk	semaglutide	GLP-1 RA	NCT05564174 (OASIS 4, oral)
Eli Lilly	tirzepatide	GIP/GLP-1 RA	NCT05822830 (SURMOUNT-5)

ClinicalTrials.gov records SURMOUNT-5 as a Phase 3 head-to-head of tirzepatide versus semaglutide 2.4 mg in adults with obesity— the primary registry anchor for class comparisons we track without publishing unsourced efficacy percentages.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Financial disclosures (verbatim filing figures only)

"Wegovy obesity care sales DKK 41.7 billion"

— Novo Nordisk Q1 2026 interim report (retrieved 2026-06-18)

Novo's Form 20-F discloses obesity-care at ~42% of net sales. Lilly's 10-K notes tirzepatide (Zepbound) launched for obesity in November 2023 as a dual GIP/GLP-1 receptor agonist.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Payer context

CMS publishes Medicare Part D coverage policy materials for outpatient drugs. Specific MA GLP-1 coverage dates require a verified CMS announcement URL before we publish dated reimbursement claims.

IntelligenceStrategic Takeaways▾

GLP-1 agonists for weight loss: 18.1k/mo US searches at 0.01 competition—class explainer with FDA labels, trials, and filing-backed Novo/Lilly data.

Analyst take — Michael Rivera

Editorial analysis; not clinical advice.

glp-1 agonists for weight loss is a textbook low-competition informational query: 18.1k/mo at 0.01 competition versus 165k/mo at 1.00 on the broader head term. Strategically, that means a class explainer can rank without fighting the full "weight loss medications" SERP—while still linking to our broader market analysis for readers who need filing-level context.

Three filing-backed signals matter for H2 2026:

1. Class query gap: 18.1k/mo at 0.01 competition rewards mechanism-of-action and comparison content—not brand-only pages.
2. Revenue booked: DKK 41.7B Wegovy obesity-care sales and ~42% obesity mix in Novo's 20-F are already in public filings.
3. Trial calendar: SURMOUNT-5 and OASIS 4 are the registry-backed catalysts; we withhold head-to-head % until primary readouts store provenance quotes.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Methodology

• Search volumes: agent_keyword, US, DataForSEO sync, cutoff 2026-06-17, retrieved 2026-06-18.
• Financial figures: Only values with evidence-package provenance (source URL, page, paragraph, quote, retrieval timestamp).
• URL policy: save_evidence rejects HTTP 404 sources; broken links stay in open_questions.

Frequently Asked Questions